UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure

Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.

Funding for the four UK Diagnostic Evidence Co-operatives (DECs), which were set up by the National Institute for Health Research (NIHR) in 2013, is coming to an end at the close next year. That means a restructuring of the activities and new methods of funding are imminent.

The DECs, which were given a budget of £4m ($5m) to cover their four years of operations, have a remit to focus on clinical validity, clinical utility, cost-effectiveness and care...

The current DEC funding will end on Dec. 31, 2017, junior health minister Nicola Blackwood (public health and innovation) explained at a recent Health and Care Innovation Expo in Manchester....

More from United Kingdom

More from Europe